Versitech, Inc.

Fundación Universitaria San Antonio

Centre for Virology, Vaccinology and Therapeutics Limited

Sinoclone Ltd

Shuofeng Yuan

Kwok Yung Yuen

Fuk Woo Jasper Chan

Johnson Yiu-Nam Lau

Jie Zhou

Yi Tsun Richard Kao

Kai Wang Kelvin To

Fan Ngai Hung

Jinxia Zhang

Helena Den Haan

Jorge Pena-García

José Pedro Cerón-Carrasco

Horacio Emilio Pérez-Sánchez

Bojian Zheng

Hin Chu

AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-α signaling, and is not a result of activation of the hosts innate immune response. Broad antiviral activity of AM580 and structurally related compounds is a due to modulation of lipogenesis so as to correct disregulation of this pathway in virus-infected cells, via inhibition of nSREPBP.

Compositions and methods for broad-spectrum antiviral therapy

Miltefosine is utilized to enhance immune response to vaccination, for example an influenza and/or coronavirus vaccination. The inventive subject matter also provides compositions and methods for enhancing viral yield in cultured cells, by application of a cannabinoid receptor agonist (such as methanandamide) to such cells. Such enhanced viral yield can be used to enhance virus production for purposes of vaccine formulation and/or to improve sensitivity of cell-based virus assays.

Compositions and methods for enhancing immune response to vaccination and improving vaccine production

The subject invention pertains to compounds and methods of using said compounds to target the multi-functional papain-like protease (PLpro) domain of the viral Nsp3, specifically F0213, F0326, and F0393 that can have broad anti-coronavirus activity, including SARS-CoV-2, MERS-CoV, and coronaviruses hCoV-229E and hCoV-OC43. F0213, F0326, and F0393 can possess a dual therapeutic functionality that suppress CoV replication via blocking viral polyprotein cleavage, as well as promote antiviral immunity by antagonizing the PLpro deubiquitinase activity.

Targeting papain-like protease for broad-spectrum coronaviruses inhibition

Methods and compounds for preventing and/or treating Zika virus (ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.

Zika virus protease inhibitors and methods of use thereof

The present invention is a method of inhibiting the replication of an influenza virus by using an antiviral compound to inhibit the binding of an influenza-virus PB2 subunit to an RNA cap. The antiviral compound may be 5-iodo-2-[(3-methyl-4-nitrobenzoyl)amino]benzoic acid; 3,3'-[(4-methylphenyl)methylene]bis(4-hydroxy-2H-chromen-2-one); or 7-(4-hydroxy-2-oxo-2H-chromen-3-yl)-6H,7H,8Hchromeno[3,4&#x2032;:5,6]pyrano[3,2-c]chromene-6,8-dione. The aforementioned antiviral compounds have successfully inhibited the replication of influenza virus in vitro and in vivo in mouse models.

Inhibiting binding of influenza-virus PB2 subunit to RNA cap

Growing community of inventors

Hong Kong, China

Shuofeng Yuan